Knowledge Library

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >

Resource Type: Article Blog
Resource Topic: Antibodies Autoimmune and Inflammatory Diseases Cell-based Assays in vivo Pharmacology Oligonucleotides Oncology

VIEW

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Cell-based Assays Oligonucleotides Oncology Tumor Models

VIEW

Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment

SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by upregulating PD-L1 expression. Consequently, combining KRAS G12C inhibitors with immune checkpoint blockers shows promising benefits. To better understand the mechanisms underlying the combined inhibition of KRAS G12C inhibitor AMG 510, and anti-PD-1 antibody nivolumab, LU-01-0361 …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Oncology Small Molecules Tumor Models

VIEW

OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

Resource Type: Article Blog Case Study
Resource Topic: Antibodies Cell-based Assays Oncology Tumor Models

VIEW

WuXi AppTec in vitro Neuroscience Services

Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However, due to poor disease and target understanding, Neuroscience drug discovery can be very challenging. An open access research platform with dedicated neuroscience specialists and integrated services will be an ideal partner throughout your drug discovery …Read More >

Resource Type: Brochure
Resource Topic: Antibodies Biochemical Assays Biomarkers Cell-based Assays Cells and Protein Science Central Nervous System & Pain Hit Finding Hit-to-Lead in vitro biology Lead Optimization Phenotypic Assays Rare Diseases Safety and Early Toxicity Small Molecules Target Identification and Validation

VIEW

OncoWuXi Newsletter November 2022

Resource Type: Newsletter
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biomarkers Cell-based Assays Cells and Protein Science Hit-to-Lead Lead Optimization Oncology

VIEW

How Does It Work? | Peptibodies

#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by fusing #therapeutic peptides to the Fc region of an antibody to create what is known as a peptibody. When the peptibody is naturally taken up by cells it binds to an Fc (antibody) receptor within …Read More >

Resource Type: Video
Resource Topic: Antibodies Cells and Protein Science Oncology Target-Specific Assays

VIEW

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Biomarkers CAR-T Cell Cell Therapies Cell-based Assays Cells and Protein Science Oncology Target Identification and Validation

VIEW

OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Resource Type: Newsletter
Resource Topic: Antibodies Cell-based Assays Hit-to-Lead in vivo Pharmacology Lead Optimization Oncology Target-Specific Assays Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!